Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Gilead Sciences
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Treatment-naive males and females, 18-65 years of age
Genotype 1 HCV infection
Negative pregnancy test for females of childbearing age
Females of childbearing age and males with female partners of childbearing age must use two forms of contraception during treatment and following the last dose of ribavirin in accordance with locally approved label for ribavirin
You may not be if
Hepatitis B or HIV infection
Pregnant or breast feeding females or male partners of pregnant females
Previous interferon or ribavirin-based therapy or investigational anti-HCV agent
History or evidence of medical condition associated with chronic liver disease other than HCV
Clareo Health | Dose-Ranging Study of Sofosbuvir in Combination With Pegylated Interferon and Ribavirin in Treatment Naïve GT 1 HCV Patients
